Screener
Halozyme Therapeutics HALO Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued outsourced manufacturing expenses | 5,181 | 11,775 |
| Taxes payable | 26,426 | 44,148 |
| Product returns and sales allowance | 44,108 | 46,594 |
| Other accrued expenses | 86,264 | 104,349 |
| Lease liability | 31,879 | 34,569 |
| Total accrued expenses | 214,542 | 270,056 |
| Less long-term portion | (102,681) | (113,863) |
| Total accrued expenses, current | $111,861 | $156,193 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's accrued expenses?
- Halozyme Therapeutics (HALO) reported accrued expenses of $86.26M in Q2 2026.
- How has Halozyme Therapeutics's accrued expenses changed year-over-year?
- Halozyme Therapeutics's accrued expenses increased by 39.0% year-over-year, from $62.04M to $86.26M.
- What is the long-term trend for Halozyme Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's accrued expenses has grown at a 38.5% compound annual growth rate (CAGR), from $20.48M to $104.35M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Halozyme Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude